港股異動 | 先健科技(1302.HK)3日累計漲幅達15% 腹主動脈覆膜支架系統獲准註冊
格隆匯11月29日丨先健科技(1302.HK)再度拉昇漲近8%,3日累計漲幅達15%。報4.27港元創近3個月新高價,總市值198億港元。日前公司用於治療腎下型腹主動脈瘤的腹主動脈覆膜支架系統獲國藥監註冊批准。該產品適應症廣泛,可用於解剖結構更為複雜的病例,並可適用於不同直徑的內臟分支。董事會相信,該產品進入該程序將縮短其註冊流程,進而加快其上市進程。預期該產品的上市將會令需要進行胸腹主動脈瘤腔內重建的患者受益,同時將擴展公司產品種類,從而推動集團於醫療器械領域的發展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.